OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Venous thromboembolism with JAK inhibitors and other immune-modulatory drugs: a Swedish comparative safety study among patients with rheumatoid arthritis
Viktor Molander, Hannah Bower, Thomas Frisell, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 189-197
Open Access | Times Cited: 65
Viktor Molander, Hannah Bower, Thomas Frisell, et al.
Annals of the Rheumatic Diseases (2022) Vol. 82, Iss. 2, pp. 189-197
Open Access | Times Cited: 65
Showing 1-25 of 65 citing articles:
Rheumatoid arthritis
Andrea Di Matteo, Joan M. Bathon, Paul Emery
The Lancet (2023) Vol. 402, Iss. 10416, pp. 2019-2033
Closed Access | Times Cited: 258
Andrea Di Matteo, Joan M. Bathon, Paul Emery
The Lancet (2023) Vol. 402, Iss. 10416, pp. 2019-2033
Closed Access | Times Cited: 258
Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE– and Institute of Medicine–based recommendations
Derek K. Chu, Lynda C. Schneider, Rachel Netahe Asiniwasis, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 132, Iss. 3, pp. 274-312
Open Access | Times Cited: 107
Derek K. Chu, Lynda C. Schneider, Rachel Netahe Asiniwasis, et al.
Annals of Allergy Asthma & Immunology (2023) Vol. 132, Iss. 3, pp. 274-312
Open Access | Times Cited: 107
Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases
Claudia A. Salinas, Anthony Louder, Jennifer M. Polinski, et al.
Rheumatology and Therapy (2022)
Open Access | Times Cited: 81
Claudia A. Salinas, Anthony Louder, Jennifer M. Polinski, et al.
Rheumatology and Therapy (2022)
Open Access | Times Cited: 81
Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme
Thomas Frisell, Hannah Bower, Matilda Morin, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 5, pp. 601-610
Open Access | Times Cited: 53
Thomas Frisell, Hannah Bower, Matilda Morin, et al.
Annals of the Rheumatic Diseases (2023) Vol. 82, Iss. 5, pp. 601-610
Open Access | Times Cited: 53
JAK inhibitor selectivity: new opportunities, better drugs?
Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 10, pp. 649-665
Closed Access | Times Cited: 18
Anniina Virtanen, Francesca Romana Spinelli, Jean Baptiste Telliez, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 10, pp. 649-665
Closed Access | Times Cited: 18
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programme
Roy Fleischmann, Jeffrey R. Curtis, Christina Charles‐Schoeman, et al.
Annals of the Rheumatic Diseases (2023), pp. ard-223916
Open Access | Times Cited: 34
Roy Fleischmann, Jeffrey R. Curtis, Christina Charles‐Schoeman, et al.
Annals of the Rheumatic Diseases (2023), pp. ard-223916
Open Access | Times Cited: 34
Baricitinib Safety for Events of Special Interest in Populations at Risk: Analysis from Randomised Trial Data Across Rheumatologic and Dermatologic Indications
Peter C. Taylor, Thomas Bieber, Rieke Alten, et al.
Advances in Therapy (2023) Vol. 40, Iss. 4, pp. 1867-1883
Open Access | Times Cited: 26
Peter C. Taylor, Thomas Bieber, Rieke Alten, et al.
Advances in Therapy (2023) Vol. 40, Iss. 4, pp. 1867-1883
Open Access | Times Cited: 26
A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience
Peter C. Taylor, Cedric Laedermann, Rieke Alten, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4527-4527
Open Access | Times Cited: 23
Peter C. Taylor, Cedric Laedermann, Rieke Alten, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 13, pp. 4527-4527
Open Access | Times Cited: 23
Review article: Novel therapies in inflammatory bowel disease – An update for clinicians
Nurulamin M Noor, Alice Bourke, Sreedhar Subramanian
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1244-1260
Open Access | Times Cited: 10
Nurulamin M Noor, Alice Bourke, Sreedhar Subramanian
Alimentary Pharmacology & Therapeutics (2024) Vol. 60, Iss. 9, pp. 1244-1260
Open Access | Times Cited: 10
Risk of extended major adverse cardiovascular event endpoints with tofacitinib versus TNF inhibitors in patients with rheumatoid arthritis: a post hoc analysis of a phase 3b/4 randomised safety study
Maya H Buch, Deepak L. Bhatt, Christina Charles‐Schoeman, et al.
RMD Open (2024) Vol. 10, Iss. 2, pp. e003912-e003912
Open Access | Times Cited: 9
Maya H Buch, Deepak L. Bhatt, Christina Charles‐Schoeman, et al.
RMD Open (2024) Vol. 10, Iss. 2, pp. e003912-e003912
Open Access | Times Cited: 9
Safety of Janus kinase inhibitors in immune-mediated inflammatory diseases—a systematic literature review informing the 2024 update of an international expert consensus statement
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access | Times Cited: 1
Victoria Konzett, Josef S Smolen, Peter Nash, et al.
Annals of the Rheumatic Diseases (2025)
Open Access | Times Cited: 1
Janus kinase inhibitors in systemic lupus erythematosus: implications for tyrosine kinase 2 inhibition
Dionysis Nikolopoulos, Ioannis Parodis
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 18
Dionysis Nikolopoulos, Ioannis Parodis
Frontiers in Medicine (2023) Vol. 10
Open Access | Times Cited: 18
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester, Jacques‐Eric Gottenberg, Roberto Caporali, et al.
Annals of the Rheumatic Diseases (2024), pp. ard-225759
Open Access | Times Cited: 7
Gerd R Burmester, Jacques‐Eric Gottenberg, Roberto Caporali, et al.
Annals of the Rheumatic Diseases (2024), pp. ard-225759
Open Access | Times Cited: 7
Recommendations for assessing the risk of cardiovascular disease and venous thromboembolism before the initiation of targeted therapies for chronic inflammatory rheumatic diseases
Jérôme Avouac, O. Fogel, Sophie Hecquet, et al.
Joint Bone Spine (2023) Vol. 90, Iss. 5, pp. 105592-105592
Open Access | Times Cited: 16
Jérôme Avouac, O. Fogel, Sophie Hecquet, et al.
Joint Bone Spine (2023) Vol. 90, Iss. 5, pp. 105592-105592
Open Access | Times Cited: 16
Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis
Qiang‐hua Wei, Hui Wang, Jianglin Zhao, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 15
Qiang‐hua Wei, Hui Wang, Jianglin Zhao, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 15
Novel insights into the management of rheumatoid arthritis: one year in review 2023
Carlo Garaffoni, Antonella Adinolfi, Alessandra Bortoluzzi, et al.
Clinical and Experimental Rheumatology (2023)
Open Access | Times Cited: 14
Carlo Garaffoni, Antonella Adinolfi, Alessandra Bortoluzzi, et al.
Clinical and Experimental Rheumatology (2023)
Open Access | Times Cited: 14
Biologics or Janus Kinase Inhibitors in Rheumatoid Arthritis Patients Who are Insufficient Responders to Conventional Anti-Rheumatic Drugs
Ennio Giulio Favalli, Gabriella Maioli, Roberto Caporali
Drugs (2024) Vol. 84, Iss. 8, pp. 877-894
Open Access | Times Cited: 6
Ennio Giulio Favalli, Gabriella Maioli, Roberto Caporali
Drugs (2024) Vol. 84, Iss. 8, pp. 877-894
Open Access | Times Cited: 6
The influence of safety warnings on the prescribing of JAK inhibitors
Mark Russell, Zijing Yang, Ben Walter, et al.
The Lancet Rheumatology (2024) Vol. 6, Iss. 3, pp. e138-e139
Closed Access | Times Cited: 5
Mark Russell, Zijing Yang, Ben Walter, et al.
The Lancet Rheumatology (2024) Vol. 6, Iss. 3, pp. e138-e139
Closed Access | Times Cited: 5
Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports
Adam Goldman, Bat-El Lugassy Galper, Amit Druyan, et al.
Seminars in Arthritis and Rheumatism (2024) Vol. 67, pp. 152461-152461
Closed Access | Times Cited: 5
Adam Goldman, Bat-El Lugassy Galper, Amit Druyan, et al.
Seminars in Arthritis and Rheumatism (2024) Vol. 67, pp. 152461-152461
Closed Access | Times Cited: 5
Increased risk of cardiovascular events under the treatments with Janus kinase inhibitors versus biological disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a retrospective longitudinal population-based study using the Japanese health insurance database
Ryoko Sakai, Eiichi Tanaka, Eisuke Inoue, et al.
RMD Open (2024) Vol. 10, Iss. 2, pp. e003885-e003885
Open Access | Times Cited: 5
Ryoko Sakai, Eiichi Tanaka, Eisuke Inoue, et al.
RMD Open (2024) Vol. 10, Iss. 2, pp. e003885-e003885
Open Access | Times Cited: 5
Clinical experience and safety of Janus kinase inhibitors in giant cell arteritis: a retrospective case series from Sweden
Per Eriksson, Oliver Skoglund, Cecilia Hemgren, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Per Eriksson, Oliver Skoglund, Cecilia Hemgren, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 12
Periplogenin inhibits pathologic synovial proliferation and infiltration in rheumatoid arthritis by regulating the JAK2/3-STAT3 pathway
Xiaoqin Zhong, Wei Feng, Lianjie Liu, et al.
International Immunopharmacology (2024) Vol. 128, pp. 111487-111487
Closed Access | Times Cited: 4
Xiaoqin Zhong, Wei Feng, Lianjie Liu, et al.
International Immunopharmacology (2024) Vol. 128, pp. 111487-111487
Closed Access | Times Cited: 4
Risk of Major Adverse Cardiovascular Events and Venous Thromboembolism with JAK Inhibitors versus TNF Inhibitors in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis
Styliani Partalidou, Dimitrios Patoulias, Kleopatra Deuteraiou, et al.
Mediterranean Journal of Rheumatology (2024) Vol. 35, Iss. Suppl 1, pp. 10-10
Open Access | Times Cited: 4
Styliani Partalidou, Dimitrios Patoulias, Kleopatra Deuteraiou, et al.
Mediterranean Journal of Rheumatology (2024) Vol. 35, Iss. Suppl 1, pp. 10-10
Open Access | Times Cited: 4
Do newly approved drugs have a worse observed safety profile than once established? A study on time trends in risks of key safety outcomes with immunomodulatory drugs against rheumatoid arthritis
Viktor Molander, Hannah Bower, Thomas Frisell, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Viktor Molander, Hannah Bower, Thomas Frisell, et al.
Annals of the Rheumatic Diseases (2025)
Open Access
Assessment of cardiovascular, thromboembolic and cancer risk in patients eligible for treatment with Janus Kinase inhibitors: The JAK-ERA multidisciplinary consensus
Lorenzo Dagna, Alessia Alunno, Nicola Farina, et al.
European Journal of Internal Medicine (2025)
Closed Access
Lorenzo Dagna, Alessia Alunno, Nicola Farina, et al.
European Journal of Internal Medicine (2025)
Closed Access
